CAR T-cell therapy: Balance of efficacy and safety

S. V. Kulemzin, V. V. Kuznetsova, M. Mamonkin, A. V. Taranin, A. A. Gorchakov

Research output: Contribution to journalReview articlepeer-review

4 Citations (Scopus)


Early results from clinical trials of autologous chimeric antigen receptor (CAR)-expressing T cells for the therapy of B-cell malignancies have encouraged extending the potency of this therapy to other cancers. However, the success of using CAR T-cells to treat patients with solid tumors has been limited. In this review, we summarize current knowledge on the design and applications of CARs for the targeted therapy of cancer. We describe existing issues that limit the widespread application of CAR T cells and discuss the optimization steps needed to further improve safety and efficacy of this therapeutic platform.

Original languageEnglish
Pages (from-to)274-287
Number of pages14
JournalMolekuliarnaia biologiia
Issue number2
Publication statusPublished - 26 May 2017


  • adoptive immunotherapy
  • cancer
  • chimeric antigen receptor
  • T-cells


Dive into the research topics of 'CAR T-cell therapy: Balance of efficacy and safety'. Together they form a unique fingerprint.

Cite this